Inventiva S.A. (IVA)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
Inventiva S.A. has not issued a press release in this window.
SEC filings
All filings →Inventiva S.A. has not filed an SEC document in this window.
Insider trades
All insider trades →Inventiva S.A. has no reported insider trades in the last 90 days.
Institutional holders
All holders →No 13F holdings have been reported for Inventiva S.A. in this window.
People at Inventiva S.A.
All people →No officers or directors have been indexed for Inventiva S.A..
Quarterly financials
Full financials →No quarterly financials have been ingested for Inventiva S.A..